《新股消息》微創腦科學(02172.HK)公開發售超購逾44倍 一手中籤率僅4.88%
由微創醫療(00853.HK)分拆的微創腦科學(02172.HK)公布招股結果,每股發售價定為24.64元,香港公開發售部分超額認購約44.27倍。每手1,000股計,一手中籤率僅4.88%,認購25手穩獲一手。該股將於明日(15日)掛牌。聯席保薦人為摩根大通及中金。
公司共引入2名基石投資者,包括Harvest及新華網(603888.SH),合共認購公司890.5萬股,佔公司已發行股本約1.5%。
此外,公司上市料淨集資約2.78億元,約30%將用於研發出血性腦卒中、腦動脈粥樣硬化狹窄及急性缺血性腦卒中治療及通路產品;約20%將用於出血性腦卒中、腦動脈粥樣硬化狹窄及急性缺血性腦卒中產品商業化;約15%將用於擴張製造設施以擴大生產規模;約20%將用於擴大全球影響力;約10%將用於透過戰略收購、投資、合作或該等戰略的結合以優化產品組合;約5%將用作營運資金及其他一般公司用途。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.